• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

正常和病理状态下组织型纤溶酶原激活物(及尿激酶)特异性抑制剂的血浆水平。

Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions.

作者信息

Juhan-Vague I, Moerman B, De Cock F, Aillaud M F, Collen D

出版信息

Thromb Res. 1984 Mar 1;33(5):523-30. doi: 10.1016/0049-3848(84)90018-5.

DOI:10.1016/0049-3848(84)90018-5
PMID:6426082
Abstract

Rapid inhibition of tissue-type plasminogen activator (t-PA) in human plasma was measured by addition of 5 IU (50 ng) of purified t-PA per ml plasma and measurement of residual t-PA in the euglobulin precipitate after 5 min incubation at 37 degrees C. The recovery of both t-PA activity and t-PA related antigen in pooled plasma from healthy individuals was approximately 90 percent, indicating that one ml of pooled normal plasma inhibits less than 1 IU or 10 ng of t-PA within 5 min. Of 20 control subjects 13 had less than 1 IU inhibitor activity; 5 subjects inhibited between 1 and 3 IU of t-PA and 2 subjects inhibited around 4.5 IU. The inhibitor titer in the latter two had however decreased to 1.8 and 2.7 IU after two days. Markedly increased rapid inhibition of t-PA (greater than 4 IU per ml) was found in plasma of patients with severe liver disease (3 of 8), pancreatitis (4 of 8), malignancy (5 of 26), but only very occasionally and transiently in that of patients with myocardial infarction (5 of 28) or deep vein thrombosis (2 of 9). Increased inhibition was observed on the first day following coronary bypass (22 of 42) or open heart (16 of 27) surgery but this had disappeared in 15 of 16 patients on the fifth postoperative day. Titration of inhibitor levels revealed maximal amounts of 30 to 50 IU per ml plasma.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

通过在每毫升血浆中加入5国际单位(50纳克)纯化的组织型纤溶酶原激活剂(t-PA),并在37℃孵育5分钟后测量优球蛋白沉淀中的残余t-PA,来测定人血浆中t-PA的快速抑制情况。健康个体混合血浆中t-PA活性和t-PA相关抗原的回收率约为90%,这表明1毫升混合正常血浆在5分钟内抑制的t-PA少于1国际单位或10纳克。20名对照受试者中,13人的抑制剂活性低于1国际单位;5名受试者抑制1至3国际单位的t-PA,2名受试者抑制约4.5国际单位。然而,后两名受试者的抑制剂效价在两天后降至1.8和2.7国际单位。在重症肝病患者(8例中的3例)、胰腺炎患者(8例中的4例)、恶性肿瘤患者(26例中的5例)的血浆中发现t-PA的快速抑制明显增加(每毫升大于4国际单位),但在心肌梗死患者(28例中的5例)或深静脉血栓形成患者(9例中的2例)中仅偶尔且短暂出现。在冠状动脉搭桥手术(42例中的22例)或心脏直视手术(27例中的16例)后的第一天观察到抑制增加,但在术后第五天,16例患者中有15例这种情况消失。抑制剂水平滴定显示,每毫升血浆中最大量为30至50国际单位。(摘要截断于250字)

相似文献

1
Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions.正常和病理状态下组织型纤溶酶原激活物(及尿激酶)特异性抑制剂的血浆水平。
Thromb Res. 1984 Mar 1;33(5):523-30. doi: 10.1016/0049-3848(84)90018-5.
2
Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.由组织型纤溶酶原激活剂的NH2末端区域和尿激酶型纤溶酶原激活剂的COOH末端区域组成的嵌合纤溶酶原激活剂在纯化系统和人血浆中的抑制作用。
Thromb Haemost. 1988 Oct 31;60(2):247-50.
3
Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation.血浆中响应内毒素刺激而产生纤溶酶原激活物的快速作用抑制剂。
J Clin Invest. 1985 Mar;75(3):818-24. doi: 10.1172/JCI111777.
4
Influence of exogenous and endogenous tissue-type plasminogen activator on the lysability of clots in a plasma milieu in vitro.外源性和内源性组织型纤溶酶原激活剂对体外血浆环境中血凝块溶解能力的影响。
Thromb Res. 1984 Aug 1;35(3):335-45. doi: 10.1016/0049-3848(84)90364-5.
5
Increased plasminogen activator inhibition levels in malignancy.恶性肿瘤中纤溶酶原激活物抑制水平升高。
Thromb Haemost. 1987 Apr 7;57(2):140-3.
6
Inhibition of one-chain and two-chain forms of human tissue-type plasminogen activator by the fast-acting inhibitor of plasminogen activator in vitro and in vivo.纤溶酶原激活物快速作用抑制剂在体外和体内对人组织型纤溶酶原激活物单链和双链形式的抑制作用
J Lab Clin Med. 1986 Jul;108(1):53-9.
7
Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications.
Circulation. 1988 Mar;77(3):660-9. doi: 10.1161/01.cir.77.3.660.
8
Dependence of fibrinolytic activity on the concentration of free rather than total tissue-type plasminogen activator in plasma after pharmacologic administration.
Circulation. 1989 Jun;79(6):1204-13. doi: 10.1161/01.cir.79.6.1204.
9
Amiloride selectively inhibits the urokinase-type plasminogen activator.
FEBS Lett. 1987 Apr 6;214(1):187-91. doi: 10.1016/0014-5793(87)80039-x.
10
The fast-acting inhibitor of tissue-type plasminogen activator in plasma is also the primary plasma inhibitor of urokinase.血浆中组织型纤溶酶原激活物的快速作用抑制剂也是尿激酶的主要血浆抑制剂。
Thromb Haemost. 1986 Feb 28;55(1):65-9.

引用本文的文献

1
A Vicious Cycle: In Severe and Critically Ill COVID-19 Patients.恶性循环:在严重和危重新冠肺炎患者中。
Front Immunol. 2022 Jun 15;13:930673. doi: 10.3389/fimmu.2022.930673. eCollection 2022.
2
Therapeutics targeting the fibrinolytic system.靶向纤维蛋白溶解系统的治疗方法。
Exp Mol Med. 2020 Mar;52(3):367-379. doi: 10.1038/s12276-020-0397-x. Epub 2020 Mar 9.
3
p53- and PAI-1-mediated induction of C-X-C chemokines and CXCR2: importance in pulmonary inflammation due to cigarette smoke exposure.p53 和 PAI-1 介导的 C-X-C 趋化因子及其受体 CXCR2 的诱导:在香烟烟雾暴露导致的肺部炎症中的重要性。
Am J Physiol Lung Cell Mol Physiol. 2016 Mar 15;310(6):L496-506. doi: 10.1152/ajplung.00290.2015. Epub 2016 Jan 8.
4
The High Affinity Binding Site on Plasminogen Activator Inhibitor-1 (PAI-1) for the Low Density Lipoprotein Receptor-related Protein (LRP1) Is Composed of Four Basic Residues.纤溶酶原激活物抑制剂-1(PAI-1)上与低密度脂蛋白受体相关蛋白(LRP1)结合的高亲和力位点由四个碱性残基组成。
J Biol Chem. 2016 Jan 8;291(2):800-12. doi: 10.1074/jbc.M115.688820. Epub 2015 Nov 10.
5
Chemical Antagonists of Plasminogen Activator Inhibitor-1: Mechanisms of Action and Therapeutic Potential in Vascular Disease.纤溶酶原激活物抑制剂-1的化学拮抗剂:作用机制及在血管疾病中的治疗潜力
J Mol Genet Med. 2014 Oct;8(3). doi: 10.4172/1747-0862.1000125.
6
Plasminogen activator inhibitor-1 in cigarette smoke exposure and influenza A virus infection-induced lung injury.纤溶酶原激活物抑制剂-1在香烟烟雾暴露和甲型流感病毒感染诱导的肺损伤中的作用
PLoS One. 2015 May 1;10(5):e0123187. doi: 10.1371/journal.pone.0123187. eCollection 2015.
7
Low Molecular Weight Antagonists of Plasminogen Activator Inhibitor-1: Therapeutic Potential in Cardiovascular Disease.纤溶酶原激活物抑制剂-1的低分子量拮抗剂:在心血管疾病中的治疗潜力
Mol Med Ther. 2012 Aug 5;1(1):101. doi: 10.4172/2324-8769.1000102.
8
Regulation of airway and alveolar epithelial cell apoptosis by p53-Induced plasminogen activator inhibitor-1 during cigarette smoke exposure injury.烟雾暴露损伤中 p53 诱导的纤溶酶原激活物抑制剂-1 对气道和肺泡上皮细胞凋亡的调节。
Am J Respir Cell Mol Biol. 2012 Oct;47(4):474-83. doi: 10.1165/rcmb.2011-0390OC. Epub 2012 May 16.
9
The plasmin-antiplasmin system: structural and functional aspects.纤溶酶-抗纤溶酶系统:结构与功能方面。
Cell Mol Life Sci. 2011 Mar;68(5):785-801. doi: 10.1007/s00018-010-0566-5. Epub 2010 Dec 7.
10
Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions.纤溶酶原激活物抑制剂-1(PAI-1):连接纤维蛋白溶解和与年龄相关的亚临床及临床状况的关键因素。
Cardiovasc Ther. 2010 Oct;28(5):e72-91. doi: 10.1111/j.1755-5922.2010.00171.x. Epub 2010 Jul 7.